Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib maintenance in BRCA-mutated ovarian cancer after first-line chemotherapy
NCT01844986Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2013
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Started Aug 2013; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01844986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01844986.